Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Nov;74(11):e13602.
doi: 10.1111/ijcp.13602. Epub 2020 Aug 16.

Real-world assessment and characteristics of men with benign prostatic hyperplasia (BPH) in primary care and urology clinics in Spain

José María Molero  1 , Bernardino Miñana  2 , Juan Manuel Palacios-Moreno  3 , Miguel Téllez Martínez-Fornes  4 , David Lorite Mingot  5 , Alfonso Agra Rolán  3 , Ágata Carreño  6 , Rafael Cuervo Pinto  5
Affiliations
Multicenter Study

Real-world assessment and characteristics of men with benign prostatic hyperplasia (BPH) in primary care and urology clinics in Spain

José María Molero et al. Int J Clin Pract. 2020 Nov.

Abstract

Objectives: To describe the real-world demographic and clinical characteristics of patients with lower urinary tract symptoms (LUTS) as a result of benign prostatic hyperplasia (BPH) in Spain.

Methodology: This observational, retrospective, multicentre study conducted in primary care and urology clinics in Spain included men aged ≥50 years diagnosed (≤8 years prior to study visit) with LUTS caused by BPH. The primary endpoint was demographic and clinical characteristics; secondary endpoints included disease progression and diagnostic tests across both healthcare settings.

Results: A total of 670 patients were included (primary care: n = 435; urology: n = 235). Most patients had moderate/severe LUTS (74.6%) and prostate volume >30 cc (81.7%), with no differences between settings. More patients had prostate-specific antigen (PSA) ≥1.5 ng/mL in primary care (74.5%) versus urology (67.7%). Progression criteria were prevalent (48.9%). Clinical criteria were more commonly used than the International Prostate Symptom Score (IPSS) to evaluate LUTS at diagnosis (primary care: clinical criteria 73.0%; IPSS: 26.9%; urology: clinical criteria 76.5%; IPSS: 23.4%). Proportion of patients with moderate/severe LUTS at diagnosis was lower using clinical criteria than IPSS, and the proportion of patients with 'worsening' LUTS (diagnosis to study visit) was higher when using clinical criteria versus IPSS. In both healthcare settings, the most commonly used diagnostic tests were general and urological clinical history and PSA.

Conclusion: Demographic and clinical characteristics of patients with BPH in Spain were similar in primary care and urology; however, assessment criteria to evaluate LUTS severity differ and are not completely aligned with clinical guideline recommendations. Increased use of recommended assessments may enhance optimal BPH management.

PubMed Disclaimer

Conflict of interest statement

JMM has received financial compensation from GSK for scientific advice on the design and development of the study protocol and from IQVIA for participating as a researcher. JMM has also participated in: advisory boards for GSK and Astellas; speaker's bureaus for GSK, Astellas and Pierre Fabre and has received compensation from GSK and Pierre Fabre for being a trial investigator. BM has participated in advisory boards and speaker's bureaus and has received compensation for travel expenses and for being a trial investigator from GSK, Janssen, Astellas, Werfen, Bayer, Sanofi and IPSEN. JMP‐M, DLM, AAR and RCP are employees of GSK and hold shareholder status in the company. MTM‐F has received compensation from GSK for travel expenses and for being a trial investigator. AC is an employee of IQVIA.

Figures

FIGURE 1
FIGURE 1
Study design. BPH, benign prostatic hyperplasia; IPSS, international prostate symptom score; LUTS, lower urinary tract symptom; SD, standard deviation
FIGURE 2
FIGURE 2
Physician (A) and patient (B) population flow diagram. †One patient had both >8 y of BPH evolution and the same data for study visit and diagnosis. BPH, benign prostatic hyperplasia
See this image and copyright information in PMC

References

    1. Minana B, Rodriguez‐Antolin A, Prieto M, Pedrosa E. Severity profiles in patients diagnosed of benign prostatic hyperplasia in Spain. Actas Urol Esp. 2013;37:544‐548. - PubMed
    1. Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005;7:S3‐S14. - PMC - PubMed
    1. Speakman MJ. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): more than treating symptoms? Eur Urol Suppl. 2008;7:680‐689.
    1. Boyle P, et al. The relationship between lower urinary tract symptoms and health status: the UREPIK study. BJU Int. 2003;92:575‐580. - PubMed
    1. Hakimi Z, Herdman M, Pavesi M, et al. Using EQ‐5D‐3L and OAB‐5D to assess changes in the health‐related quality of life of men with lower urinary tract symptoms associated with benign prostatic hyperplasia. Qual Life Res. 2017;26:1187‐1195. - PubMed

Publication types

Grants and funding